Lennox–Gastaut syndrome (LGS) is a complex, rare, and severe childhood-onset epilepsy. It is characterized by multiple and concurrent seizure types, cognitive dysfunction, and slow spike waves on electroencephalogram (EEG). Typically, it presents in children aged 3–5 years and can persist into adulthood.
Corpus callosotomy is a surgical procedure used for treating refractory generalized seizures caused due to Lennox-Gastaut syndrome (LGS). However, this surgical procedure involves craniotomy with microdissection. Therefore, companies are focusing on the development of minimally invasive procedures such as MR-guided laser interstitial thermal therapy (MRg-LITT). MRg-LITT has emerged as a safe, effective, and durable alternative of traditional open corpus callosotomy. The efficacy of MRg-LITT is also being tested in advanced surgical ablation of epileptogenic foci and corpus callosotomy. This will further boost its adoption in LGS treatment. Such advancements in surgical treatments will be one of the key trends that will impact LGS market growth in the coming years.
In 2018, the global Lennox-Gastaut Syndrome Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Lennox-Gastaut Syndrome Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Lennox-Gastaut Syndrome Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
Eisai Co., Ltd.
GlaxoSmithKline plc.
H. Lundbeck A/S
Johnson & Johnson Services, Inc.
Supernus Pharmaceuticals, Inc
...
Market segment by Type, the product can be split into
Non-surgical Treatment
Surgical Treatment
Market segment by Application, split into
Seizures
Ocular Abnormality
EEG Findings
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Lennox-Gastaut Syndrome Treatment status, future forecast, growth opportunity, key market and key players.
To present the Lennox-Gastaut Syndrome Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Lennox-Gastaut Syndrome Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Summary:
Get latest Market Research Reports on Lennox-Gastaut Syndrome Treatment. Industry analysis & Market Report on Lennox-Gastaut Syndrome Treatment is a syndicated market report, published as Global Lennox-Gastaut Syndrome Treatment Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Lennox-Gastaut Syndrome Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.